Technical Analysis for NGEN - Nervgen Pharma Corp
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -2.23% | |
| Fell Below 20 DMA | Bearish | -1.55% | |
| Crossed Above 20 DMA | Bullish | -2.23% | |
| Fell Below 20 DMA | Bearish | 1.24% | |
| NR7 | Range Contraction | 1.24% | |
| Narrow Range Bar | Range Contraction | 1.24% | |
| Inside Day | Range Contraction | 1.24% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 8 hours ago |
| Down 1% | about 12 hours ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 3% | 1 day ago |
| Down 2% | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-08-07
NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of nerve damage. Its product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University of Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.98 |
| 52 Week Low | 1.58 |
| Average Volume | 85,544 |
| 200-Day Moving Average | 2.383 |
| 50-Day Moving Average | 2.489 |
| 20-Day Moving Average | 2.940 |
| 10-Day Moving Average | 2.912 |
| Average True Range | 0.156 |
| RSI (14) | 53.70 |
| ADX | 21.25 |
| +DI | 25.894 |
| -DI | 20.538 |
| Chandelier Exit (Long, 3 ATRs) | 2.832 |
| Chandelier Exit (Short, 3 ATRs) | 2.938 |
| Upper Bollinger Bands | 3.206 |
| Lower Bollinger Band | 2.675 |
| Percent B (%b) | 0.34 |
| BandWidth | 18.039 |
| MACD Line | 0.099 |
| MACD Signal Line | 0.139 |
| MACD Histogram | -0.0397 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.915 | ||||
| Resistance 3 (R3) | 2.913 | 2.892 | 2.905 | ||
| Resistance 2 (R2) | 2.892 | 2.876 | 2.893 | 2.902 | |
| Resistance 1 (R1) | 2.873 | 2.867 | 2.883 | 2.875 | 2.898 |
| Pivot Point | 2.852 | 2.852 | 2.856 | 2.853 | 2.852 |
| Support 1 (S1) | 2.833 | 2.836 | 2.843 | 2.835 | 2.812 |
| Support 2 (S2) | 2.812 | 2.827 | 2.813 | 2.808 | |
| Support 3 (S3) | 2.793 | 2.812 | 2.805 | ||
| Support 4 (S4) | 2.795 |
